Abstract
Background: RNA interference is a promising therapeutic tool for the treatment of a variety of diseases, with great potential for cancer therapy. Small interfering RNA (siRNA), however, presents several drawbacks that hamper its therapeutic application. Lipid nanoparticles, including liposomes, are delivery systems with great potential for siRNA delivery, protecting it from degradation, enhancing its cell uptake with the ability of controlled release. However, non-specific delivery and side effects could potentially limit the in vivo application. Therefore, targeting lipid nanoparticles to overexpressed receptors of cancer cells represents a strategy for better therapeutic outcome, with improved efficacy and reduced toxicity. For this purpose, lipid nanoparticles could be functionalized with several moieties that can be recognized by cancer cells more than by normal cells. These ligands include folate, transferrin, peptides, oligosaccharides, monoclonal antibodies and aptamers.
Methods: In this paper, we reviewed functionalization strategies and addressed the major in vitro and in vivo findings in the field of cancer treatment with siRNA.
Results: Many papers showed enhanced siRNA delivery by targeted liposomes, resulting in enhanced drug uptake and better cytotoxicity, with consequent better tumor growth control in xenograft studies.
Conclusion: siRNA delivery mediated by functionalized liposomes is promising, but clinical trials need to be conducted.
Keywords: siRNA, targeting, lipid nanoparticle, liposomes, cancer therapy, toxicity.
Current Pharmaceutical Design
Title:Targeted Liposomes for siRNA Delivery to Cancer
Volume: 24 Issue: 23
Author(s): Josimar O. Eloy, Raquel Petrilli, Giovanni Loureiro Raspantini and Robert J. Lee*
Affiliation:
- Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, Ohio,United States
Keywords: siRNA, targeting, lipid nanoparticle, liposomes, cancer therapy, toxicity.
Abstract: Background: RNA interference is a promising therapeutic tool for the treatment of a variety of diseases, with great potential for cancer therapy. Small interfering RNA (siRNA), however, presents several drawbacks that hamper its therapeutic application. Lipid nanoparticles, including liposomes, are delivery systems with great potential for siRNA delivery, protecting it from degradation, enhancing its cell uptake with the ability of controlled release. However, non-specific delivery and side effects could potentially limit the in vivo application. Therefore, targeting lipid nanoparticles to overexpressed receptors of cancer cells represents a strategy for better therapeutic outcome, with improved efficacy and reduced toxicity. For this purpose, lipid nanoparticles could be functionalized with several moieties that can be recognized by cancer cells more than by normal cells. These ligands include folate, transferrin, peptides, oligosaccharides, monoclonal antibodies and aptamers.
Methods: In this paper, we reviewed functionalization strategies and addressed the major in vitro and in vivo findings in the field of cancer treatment with siRNA.
Results: Many papers showed enhanced siRNA delivery by targeted liposomes, resulting in enhanced drug uptake and better cytotoxicity, with consequent better tumor growth control in xenograft studies.
Conclusion: siRNA delivery mediated by functionalized liposomes is promising, but clinical trials need to be conducted.
Export Options
About this article
Cite this article as:
Eloy O. Josimar , Petrilli Raquel , Raspantini Loureiro Giovanni and Lee J. Robert *, Targeted Liposomes for siRNA Delivery to Cancer, Current Pharmaceutical Design 2018; 24 (23) . https://dx.doi.org/10.2174/1381612824666180807121935
DOI https://dx.doi.org/10.2174/1381612824666180807121935 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Metabolism of Anthocyanins
Current Drug Metabolism Treatment Directed to Signalling Molecules in Patients with Advanced Differentiated Thyroid Cancer
Anti-Cancer Agents in Medicinal Chemistry Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 2: Calciferol and the Significance of Nutrient Supplements
Inflammation & Allergy - Drug Targets (Discontinued) Redox Environment and its Meaning for Breast Cancer Cells Fate
Current Cancer Drug Targets Radiation Therapy in the Management of Lung Cancer
Current Respiratory Medicine Reviews Topoisomerase I-DNA Complex Stability Induced by Camptothecins and Its Role in Drug Activity&#
Current Medicinal Chemistry - Anti-Cancer Agents Macrocyclic Proteasome Inhibitors
Current Medicinal Chemistry Biomarkers in Non-Small Cell Lung Cancer: Perspectives of Individualized Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry Novel Systemic Cardiovascular Disease Biomarkers
Current Molecular Medicine Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
Current Cancer Drug Targets Using Fragment-Based Technologies to Target Protein-Protein Interactions
Current Pharmaceutical Design The Role of FLT3 Kinase as an AML Therapy Target
Current Pharmaceutical Design Recent Patents on Imaging Nanoprobes for Brain Tumor Diagnosis and Therapy
Recent Patents on Biotechnology A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Circadian Rhythm of Blood Pressure in Diabetes Mellitus: Evidence, Mechanisms and Implications
Current Diabetes Reviews Dietary Fiber Gap and Host Gut Microbiota
Protein & Peptide Letters RhoGEFs in Cell Motility: Novel Links Between Rgnef and Focal Adhesion Kinase
Current Molecular Medicine Development of Novel Therapeutic Strategies for Lung Cancer: Targeting the Cholinergic System
Current Medicinal Chemistry Di- and Sesquiterpenoids from Cystoseira Genus: Structure, Intra-molecular Transformations and Biological Activity
Mini-Reviews in Medicinal Chemistry microRNA Involvement in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry